Pacira BioSciences/$PCRX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Pacira BioSciences
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
- Ticker
- $PCRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 827
- Headquarters
- Brisbane, United States
- Website
- www.pacira.com
PCRX Metrics
BasicAdvanced
$1.4B
103.22
$0.35
0.27
-
Price and volume
Market cap
$1.4B
Beta
0.27
52-week high
$36.46
52-week low
$18.80
Average daily volume
1.6M
Financial strength
Current ratio
5.042
Quick ratio
3.213
Long term debt to equity
0.598
Total debt to equity
0.613
Interest coverage (TTM)
2.12%
Profitability
EBITDA (TTM)
123.966
Gross margin (TTM)
79.21%
Net profit margin (TTM)
1.96%
Operating margin (TTM)
4.40%
Effective tax rate (TTM)
17.06%
Revenue per employee (TTM)
$900,000
Management effectiveness
Return on assets (TTM)
1.48%
Return on equity (TTM)
2.05%
Valuation
Price to earnings (TTM)
103.222
Price to revenue (TTM)
2.025
Price to book
2.15
Price to tangible book (TTM)
3.94
Price to free cash flow (TTM)
8.417
Free cash flow yield (TTM)
11.88%
Free cash flow per share (TTM)
4.314
Growth
Revenue change (TTM)
5.71%
Earnings per share change (TTM)
-112.53%
3-year revenue growth (CAGR)
3.69%
10-year revenue growth (CAGR)
10.84%
3-year earnings per share growth (CAGR)
32.53%
10-year earnings per share growth (CAGR)
1.30%
What the Analysts think about PCRX
Analyst ratings (Buy, Hold, Sell) for Pacira BioSciences stock.
Analyst projections of the future price of Pacira BioSciences stock.
Bulls say / Bears say
Viatris’s agreement to acquire Pacira creates a nearer-term corporate catalyst and a route to realise value sooner than Pacira’s clinical pipeline could. The announcement confirms a buyer is in place, although completion is not assured. (Viatris)
EXPAREL’s reimbursement reach is widening: UnitedHealthcare now reimburses it separately in outpatient settings for about 40 million members, bringing total coverage to roughly 150 million lives. Better coverage could help hospitals and surgery centres adopt the drug. (GlobeNewswire)
PCRX-201 offers longer-term growth potential beyond the marketed drugs. Two-year Phase 1 follow-up found the gene therapy well tolerated and reported exploratory improvements in knee pain, stiffness and function among participants who remained in the study. (GlobeNewswire)
EXPAREL’s sales growth is modest: second-quarter net sales rose 3%, below 4% volume growth, as product mix and GPO discounts absorbed some of the added volume. (GlobeNewswire)
Generic competition threatens Pacira’s main revenue source. The company disclosed patent challenges from WhiteOak and Qilu, with the lawsuits ongoing and their outcomes uncertain. (MarketScreener)
Viatris’s acquisition is still an agreement, not a completed deal, so shareholders face the risk that it does not close. In that case, investors would again depend on Pacira’s standalone growth while its EXPAREL patent litigation remains unresolved. (Viatris, MarketScreener)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2026.
PCRX Financial Performance
Revenues and expenses
PCRX Earnings Performance
Company profitability
Upcoming events
No upcoming events
PCRX News
AllArticlesVideos
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)
Newsfile Corp3 days ago
2 Stocks Drawing Bearish Options Activity Today
Schaeffers Research3 days ago
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
Business Wire3 days ago
Funds containing PCRX
AllUSDGBPEUR
Fund name | Fund size | $PCRX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.10% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.10% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.08% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.08% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.